Intelgenx Technologies Corp IGXT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IGXT is a good fit for your portfolio.
News
-
IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
-
IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
-
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
-
IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
-
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
-
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
-
IntelGenx Announces Voting Results on Election of Directors
-
Toronto Stocks Edge Lower; Volt Lithium Shares Drop on C$6 Million Marketed Public Offering
Trading Information
- Previous Close Price
- $0.17
- Day Range
- $0.16–0.17
- 52-Week Range
- $0.09–0.22
- Bid/Ask
- $0.15 / $0.29
- Market Cap
- $29.17 Mil
- Volume/Avg
- 37,230 / 106,643
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 27.75
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. The company focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer, and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and the United States. The company generates the majority of its revenue from Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 50
- Website
- https://www.intelgenx.com
Valuation
|
Metric
|
IGXT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 27.75 |
Price/Cash Flow | — |
Price/Earnings
IGXT
Financial Strength
|
Metric
|
IGXT
|
|---|---|
Quick Ratio | 0.10 |
Current Ratio | 0.13 |
Interest Coverage | −4.27 |
Quick Ratio
IGXT
Profitability
|
Metric
|
IGXT
|
|---|---|
Return on Assets (Normalized) | −139.88% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −216.01% |
Return on Assets
IGXT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Gfytjjhck | Jvj | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vdmnjmvy | Jpbxrj | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rhlqnjggp | Dgmxlw | $118.7 Bil | |||
| Moderna Inc
MRNA
| Sxgqfmfxg | Lgnmd | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vqpmcmzn | Yrlwg | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Rctnxssp | Hzj | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Byfzttt | Byfh | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vbzxtpd | Zzgvytz | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Ksxjvnrgz | Whsf | $15.0 Bil | |||
| Incyte Corp
INCY
| Kgbfymzk | Vvmfyf | $13.5 Bil |